MoneyWorks4Me

Pharmaids Pharmaceutical informs about compliance report

13 May 2024 Evaluate

Pursuant to Regulation 24A of the Listing Regulations read with SEBI Circular No. CIR/CFD/CMDI/ 27/2019 dated February 8 2019 and Circular No: NSE/CML/ 2023/30 dated April 10, 2023, Pharmaids Pharmaceutical has informed that it enclosed the Annual Secretarial Compliance Report for the Financial Year ended March 31, 2024, issued by Kashinath Sahu & Co, Practicing Company Secretary.

The above information is a part of company’s filings submitted to BSE.

Pharmaids Pharma Share Price

32.24 0.06 (0.19%)
21-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1900.90
Dr. Reddys Labs. 1175.00
Cipla 1426.20
Lupin 2193.00
Zydus Lifesciences 1120.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: